PATENT CLAIM ANALYSIS

Application Number: 16321197
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-06
Patent Classification: ["424", "468000"]

Abstract:
The invention relates to an improved tetrahydrobiopterin formulation for treating patients affected by hyperphenylalaninemia. More specifically, the formulation of the invention permits a prolonged residence of tetrahydrobiopterin in the plasma, and/or a higher concentration of sapropterin in the plasma, enabling notably the treatment of HPA patients that would usually not be classified as responders to tetrahydrobiopterin loading test, and therefore left without any pharmacological treatment opportunity, but only with a strictly controlled protein diet.

Claim (Index 17):
The method of  claim 16 , wherein the second formulation is administered from 2 to 6 times per day in an amount of between 0.33 mg/kg to 10 mg/kg per dose, with the first dose being administered within 30 minutes before or after the administration of the first fast-release formulation.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 99.0
- Lexical Diversity: 1.39655
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12508209', '11143887', '13297644', '15255467', '12106621']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7031001681407792
- 35 USC 102 Novelty (BERT): 0.5265896432982673
- Combined Prediction Score: 0.6854491156565281
- Mean Citation Score: 268.265662
- Max Citation Score: 283.91745
- Similarity Product: 165.30897194707987

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test